Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old

X
Trial Profile

Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
  • Indications Traveller's diarrhoea
  • Focus Adverse reactions; First in man
  • Sponsors Eveliqure Biotechnologies
  • Most Recent Events

    • 23 Feb 2022 According to an Eveliqure Biotechnologies media release, results of this study were published in the peer-reviewed journal Vaccines
    • 23 Feb 2022 Results published in the an Eveliqure Biotechnologies Media Release
    • 23 Feb 2022 According to an Eveliqure Biotechnologies media release, Status changed from planning to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top